Search

Displaying results 2461 - 2470 of 10000 in total
  1. Drug

    Polysilicone-15

    go.drugbank.com/drugs/DB11271
    Approved

    Polysilicone-15 is a silicone based UVB absorber . The compound is a colorless to pale yellow viscous liquid which is soluble in organic solvents of medium polarity and insoluble in water . It is the first polymeric UVB filer consisting ...

  2. Drug

    Thiothixene

    go.drugbank.com/drugs/DB01623
    Approved

    A thioxanthine used as an antipsychotic agent. Its effects are similar to the phenothiazine antipsychotics.

  3. Drug

    Vibegron

    go.drugbank.com/drugs/DB14895
    ApprovedInvestigational

    On December 23, 2020, vibegron was approved for the same indication in adults. It is available as oral tablets under the market name GEMTESA.

  4. Drug

    Guanoxan

    go.drugbank.com/drugs/DB13211
    Approved

    Guanoxan was approved in the UK but was withdrawn from the market due to hepatotoxicity. … Guanoxan is an antihypertensive agent similar in its mechanism of action to guanethidine; may cause liver damage.

  5. Drug

    Baloxavir marboxil

    go.drugbank.com/drugs/DB13997
    ApprovedInvestigational

    [L4779] It was also approved by the European Commission on January 7, 2021.[L45241] … [A251760] Baloxavir marboxil was first globally approved in Japan in February 2018,[A39895] followed by the US approval in October, 2018.

  6. Drug

    Aprocitentan

    go.drugbank.com/drugs/DB15059
    ApprovedInvestigational

    [A263386,L50261] Aprocitentan was approved by the FDA in March 2024 for the treatment of hypertension in patients inadequately controlled with standard therapy.

  7. Drug

    Cilostazol

    go.drugbank.com/drugs/DB01166
    ApprovedInvestigational

    It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reducing calcium-induced contractions.

  8. Drug

    RGX-501

    go.drugbank.com/drugs/DB17639
    Investigational

    RGX-501 is an adeno-associated virus vector 8 (AAV8)-mediated gene therapy that delivers a functional copy of the human low-density lipoprotein receptor (LDLR) gene to liver cells.

  9. Drug

    Danicopan

    go.drugbank.com/drugs/DB15401
    ApprovedInvestigational

    [A263501] Unfortunately, complement C5 inhibition does not address C3-mediated extravascular hemolysis, which occurs earlier in the complement cascade within the alternative pathway. … [A263506] It was subsequently approved by the FDA in March 2024.[L50386]

    Synonyms: (2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide, (2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidine-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridine-2-yl)-4-fluoropyrrolidine-2-carboxamide
  10. Drug

    Nebivolol

    go.drugbank.com/drugs/DB04861
    ApprovedInvestigational

    [A182579] Nebivolol and other beta blockers are generally not first line therapies as many patients are first treated with thiazide diuretics.

    Mixtures: LOBI HZProducts: CORETEL-N